Genmab — December 2019
-
-
Såfremt Darzalex når 3mia USD i salg i pr og Genmab så fremadrettet får 20% af salget mon ikke det så resulteret i forhøjede kursmål 1750-2000
-
Impact of Daratumumab Monotherapy on Bone Parameters in Relapsed Refractory Multiple Myeloma Pts - https://www.youtube.com/watch?v=LxVzZtY-Hf8
-
Danske Bank hæver target til 1750 fra 1650
-
Julehilsen fra Genmab:
Tak for et godt samarbejde i det forgangne år.
Godt nytår og glædelig jul til dig og alle skribenter og læsere på ProInvestor.
-
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
Company AnnouncementGenmab and CureVac enter broad strategic partnership
Companies to conduct joint research on first program; option for Genmab to initiate three additional programs during 5-year research term
Genmab will provide CureVac with a USD 10 million upfront payment and make an equity investment in CureVac of 20 million euro
CureVac eligible to receive milestones between USD 275 million and US
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind